NCT05328336招募中2 期
A Single-arm, Multicenter, Open Clinical Trial of the Efficacy and Safety of Tislelizumab in Combination With Nab-Paclitaxel for the Perioperative Treatment of Muscle-invasive Bladder Cancer
Tianjin Medical University Second Hospital1 个研究点 分布在 1 个国家目标入组 74 人开始时间: 2021年11月11日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 74
- 试验地点
- 1
- 主要终点
- complete response (CR) rate
研究概览
简要总结
This is a single-arm, open-label, multicenter clinical trial to investigate the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as perioperative treatment in patients with muscle-invasive bladder cancer (MIBC) prior to cystectomy or complete TURBT. Patients will receive perioperative treatment with tislelizumab in combination with nab-paclitaxel every 3 weeks for 3 treatment cycles over 9 weeks followed by radical cystectomy or complete TURBT.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide written informed consent.
- •Ability to comply with the protocol.
- •Age ≥ 18 years.
- •Suitable and planned for complete transurethral resection of bladder tumor or radical cystectomy
- •At least one measurable lesion meeting RECISTv1.1 criteria prior to transurethral bladder tumor electrosurgery (MR/CT long diameter of ≥10 mm or short diameter of ≥15 mm of enlarged lymph node required for this measurable lesion according to RECISTv1.1)
- •Histopathologically confirmed urothelial carcinoma. Patients with mixed histologies are required to have a dominant (i.e. 50% at least) urothelial cell pattern.
- •Clinical stage T2-T4a NxM0 disease by CT (or MRI).
- •Expected survival time is greater than 12 weeks.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 1 or
- •Agree to provide tissue examination specimens (used to detect PD-L1 expression, tumor mutation burden, etc.)
- •The organ function level must meet the following requirements:
- •Hematological indicators: absolute neutrophil count ≥1.5×10^9/ L, platelet count ≥80×10^9/L, hemoglobin ≥6.0 g/dL (can be maintained by symptomatic treatment);
- •Liver function: total bilirubin ≤ 1.5 times the upper limit of normal value, alanine aminotransferase and aspartate aminotransferase
- •≤ 2.5 times the upper limit of normal value, if there is intrahepatic transaminase ≤ 5 times the upper limit of normal value;
- •Renal function: creatinine ≤ 2 times the upper limit of normal, and creatinine clearance ≥ 30 ml/min;
排除标准
- •Receive live attenuated vaccines within 4 weeks before treatment or plan to receive live attenuated vaccines during the study period.
- •Active, known or suspected autoimmune diseases.
- •Known history of primary immunodeficiency.
- •Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- •Female patients who are pregnant or breastfeeding.
- •Untreated acute or chronic active hepatitis B or C infection. In the case of patients receiving antiviral therapy, the doctor will judge whether they are eligible for enrollment according to the individual conditions of the patient while monitoring the virus copy number.
- •Have used immunosuppressive drugs in the past 4 weeks before starting treatment, excluding nasal spray and inhaled corticosteroids or physiological doses of systemic steroids (that is, prednisolone or equivalent physiological doses of no more than 10 mg/day) Other corticosteroids).
- •Those who are known or suspected to be allergic to tislelizumab and nab paclitaxel.
- •Have a clear history of active tuberculosis.
- •Have received PD-1/PD-L1/CTLA-4 antibody or other immunotherapy in the past.
- •Those who are participating in other clinical research.
- •Reproductive men or women who are likely to become pregnant have not taken reliable contraceptive measures.
- •Uncontrolled concurrent diseases include but are not limited to:
- •HIV-infected persons (HIV antibody positive).
- •Serious infections that are active or poorly clinically controlled.
- •There are serious or uncontrollable systemic diseases (such as severe mental, neurological, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, liver or kidney diseases, uncontrolled hypertension [ie refers to After drug treatment, it is still greater than or equal to CTCAE Grade 2 hypertension]) evidence.
- •Active bleeding or new thrombotic disease.
研究组 & 干预措施
Experimental: Tislelizumab and Nab Paclitaxel
Experimental
Experimental: Tislelizumab and Nab Paclitaxel Tislelizumab 200mg IV on day 1 in combination with nab paclitaxel 200mg IV on day 2 every 3 weeks for 3 cycles followed by surgery.
干预措施: Tislelizumab Nab paclitaxel (Drug)
结局指标
主要结局
complete response (CR) rate
时间窗: At the time of complete transurethral resection of bladder tumor or radical cystectomy (within 12 weeks of the first dose of tislelizumab)
defined as the percentage of participants having CR. CR is defined as absence of viable tumor in examined tissue
次要结局
- Number of subjects that reach pathological downstaging to <pT2(At the time of complete transurethral resection of bladder tumor or radical cystectomy (within 12 weeks of the first dose of tislelizumab))
- Event-free survival (EFS)(up to 3 years)
- Objective response rate (ORR)(At the time of complete transurethral resection of bladder tumor or radical cystectomy (within 12 weeks of the first dose of tislelizumab))
- Overall Survival (OS)(up to 3 years)
- Number of adverse events and severity by grade (CTCAE)(up to 1 years)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
PROACTIVE-HF IDE Trial Heart Failure NYHA Class IIIHeart Failure NYHA Class IIINCT04089059Endotronix, Inc.738
已完成
3 期
Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia AHemophilia ANCT03815318Sinocelltech Ltd.73
尚未招募
1 期
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast CancerMetastatic Triple-negative Breast CancerNCT05746728Huihua Xiong45
已完成
3 期
A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza InfectionInfluenza, HumanNCT01527110GlaxoSmithKline21
招募中
不适用
A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSLPrimary Central Nervous System LymphomaNCT06445257Huai'an First People's Hospital30